US OptionsDetailed Quotes
NVAX240823C9000
- 2.87
- -0.93-24.47%
15min DelayClose Aug 23 16:00 ET
2.87High2.87Low
2.87Open3.80Pre Close2 Volume3 Open Interest9.00Strike Price574.00Turnover0.00%IV-1.00%PremiumAug 23, 2024Expiry Date2.99Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.19Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Novavax Stock Discussion
Sign in to post a comment
$Novavax (NVAX.US)$ friendly remind, time to have a shot for the flu season 😘
1
4
$Novavax (NVAX.US)$ we are so back
2
$Novavax (NVAX.US)$
yesterday action
- pre market and early market down 18 percent after result release
- within the same day , recovered all the losses and gain 10 percents
my intepretation
1) trader deliberate sell down , flushing out weak holders and triggering stop loss
2) big fish like sanofi coming in to collect shares at low
Going ahead, with the results out of the way and mid term finance sorted
i only see upside at this price point ( sanofi brought 10 , SK at 13 ) with near term mult...
yesterday action
- pre market and early market down 18 percent after result release
- within the same day , recovered all the losses and gain 10 percents
my intepretation
1) trader deliberate sell down , flushing out weak holders and triggering stop loss
2) big fish like sanofi coming in to collect shares at low
Going ahead, with the results out of the way and mid term finance sorted
i only see upside at this price point ( sanofi brought 10 , SK at 13 ) with near term mult...
4
$Novavax (NVAX.US)$
★★ Key Points Summary
Sanofi Partnership Progress:
- Partnership Terms: Novavax's collaboration with Sanofi involves an upfront payment and equity investment totaling $570 million, with potential milestone payments reaching $700 million. The deal includes long-term royalties from COVID-19 vaccine and Matrix-M adjuvant sales.
- Commercialization Transition: Sanofi will take over commercialization in 2025, allowing Novavax to shift focus to research...
★★ Key Points Summary
Sanofi Partnership Progress:
- Partnership Terms: Novavax's collaboration with Sanofi involves an upfront payment and equity investment totaling $570 million, with potential milestone payments reaching $700 million. The deal includes long-term royalties from COVID-19 vaccine and Matrix-M adjuvant sales.
- Commercialization Transition: Sanofi will take over commercialization in 2025, allowing Novavax to shift focus to research...
1
$Novavax (NVAX.US)$
imagine the pain
imagine the pain
1
$Novavax (NVAX.US)$ Will we hit $11 today?
3
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Novavax (NVAX.US)$ very good performance
1
$Novavax (NVAX.US)$ Does earning report come out at 8:30pm (SGT)??
1
$Novavax (NVAX.US)$ $Sanofi (SNY.US)$ $Moderna (MRNA.US)$ $Pfizer (PFE.US)$
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
11
1
No comment yet
Dafydd Green : And Covid!
KC67 Chan : More like mpox
MoneySucker : no way...
104157900 KC67 Chan : imagine they create vaccine for mpox